Clinical trial
Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients…
NCT00201760 · Kari Kendra, Other · Completed
Key facts
| NCT number | NCT00201760 |
|---|---|
| Title | Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer |
| Official title | A Randomized Phase II Study of Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer |
| Lead sponsor | Kari Kendra, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, Trastuzumab, Cisplatin |
| Enrollment | 10 |
| Start date | Feb 25, 2005 |
| Primary completion | Oct 31, 2009 |
| Completion | Oct 31, 2009 |
| First posted | Sep 20, 2005 |
| Last update posted | Dec 27, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: